Brief: Medesis Pharma FY Operating Loss Widens To EUR 1.0 Mln

Medesis Pharma SA

14/04/2021 07:22

April 14 (Reuters) - MEDESIS PHARMA SA  ALMDP.PA :
    * FY NET REVENUE EUR 0.2 MILLION VERSUS EUR 0.2 MILLION YEAR
AGO
    * FY OPERATING LOSS EUR 1.0 MILLION VERSUS LOSS EUR 0.8
MILLION
YEAR AGO
    * ADVANCEMENT OF NANOMANGANESE PROGRAM FOR TREATMENT OF
SEVERE
FORMS OF COVID-19, SHOULD SHOW RESULTS IN LATE SUMMER 2021
    * FY FINANCIAL LOSS EUR 58,600 VERSUS LOSS EUR 0.4 MILLION
YEAR
AGO
    * THE TWO CLINICAL PROGRAMS FOR TREATMENT OF
NEURODEGENERATIVE
DISEASES (ALZHEIMER/HUNTINGTON) COULD BE FINALIZED AT END
2022/BEG 2023
    * POSITIVE RESULTS FOR NANOMANGANESE WOULD MAKE IT POSSIBLE
TO
APPLY FOR A TEMPORARY AUTHORIZATION OF USE TO ENTER MARKET AT
END OF 2021

Source text: https://bit.ly/3uMhSRM
Further company coverage:  ALMDP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))